is active in nonstressed conditions, our finding provides a novel insight into the signaling cascade involved in the regulation of MdmX localization and for regulation of Mdm2 localization and stability.
Mdm2 and MdmX function as cellular regulators of the p53 tumor suppressor protein. Intriguingly, the activities of these proteins are interdependent; MdmX stabilizes Mdm2, enabling its activities towards p53, but it also requires Mdm2 for its nuclear localization. Here Keywords: CDK2; Mdm2; MdmX; nuclear export; phosphorylation; stability Mdm2 is a RING-finger protein with potent E3 ligase activity that plays an important role in the regulation of p53 transcription and stability (Haupt et al., 1997; Honda and Yasuda, 2000; Alarcon-Vargas et al., 2003) . In turn, p53 regulates Mdm2 at the protein level, while Mdm2 limits its own availability through self-ubiquitination (Haupt et al., 1997; Fuchs et al., 1998; Fang et al., 2000) . The Mdm2-related protein MdmX contains domains homologous to those of Mdm2, including the p53 binding domain, a zinc-finger motif and a Cterminal RING-finger domain (Sharp et al., 1999; Tanimura et al., 1999) . Although MdmX was not found capable of ubiquitinating and degrading Mdm2, it has been shown to modulate ubiquitination and transactivation of p53 (Shvarts et al., 1997; Stad et al., 2001; Finch et al., 2002; Sabbatini and McCormick, 2002; Ghosh et al., 2003) . Mdm2 and MdmX have also been shown to cooperate in p53 inactivation (Badciong and Haas, 2002) . The importance of both Mdm2 and MdmX in p53 regulation is illustrated by genetic data indicating that the absence of either is incompatible with survival beyond day 13 during development and that in both cases the lethality can be rescued by a cross with a p53-null background (Parant J et al., 2001; Migliorini et al., 2002b) .
The role of Mdm2 as an oncogene is well established, and recent data point to the possibility that MdmX may also elicit similar functions (Danovi et al., 2004) . MdmX was amplified in a series of gliomas that lacked changes in either Mdm2 or p53 (Riemenschneider et al., 1999; Ramos et al., 2001 ).
Mdm2 and MdmX form both homo-and heterooligomers in vitro and in vivo; the hetero-oligomers exhibit a more stable association that depends on the presence of an intact RING domain. Further, the halflife of Mdm2 increases upon expression of the wt but not the RING-mutant form of MdmX, suggesting that heterodimerization serves to stabilize Mdm2 (Tanimura et al., 1999) . Stabilization of Mdm2 in response to Mdm2-MdmX interaction is due to inhibition of Mdm2 E3 ligase activity, which attenuates Mdm2 ability to mediate self-ubiquitination (Sharp et al., 1999) .
Unlike Mdm2, whose expression is cell-cycle-dependent, MdmX exhibits a stable level of expression that is not altered during cell growth or differentiation (Shvarts et al., 1996; Jackson and Berberich, 1999; Parant JM et al., 2001) . Rather, MdmX's subcellular localization is important in regulation of its activity. In most cells MdmX is localized primarily within the cytoplasm. However, upon increased expression of either Mdm2 or p53, MdmX is translocated into the nucleus (Gu et al., 2002; Migliorini et al., 2002a, b) . DNA damage also causes efficient nuclear translocation of MdmX independently of p53 or Mdm2 activity (Li et al., 2002) . These studies indicate that MdmX is a relatively stable protein that contributes to Mdm2 stability and activity via their heterodimerization and localization.
In a search for protein kinases that affect Mdm2 stability, we found that p38/MAPK markedly increased steady-state levels of Mdm2 (data not shown). However, mutation within the single putative MAPK kinase site on Mdm2 (aa 215) did not impede its stability, suggesting that the p38/MAPK effect may be indirect. Given the association of MdmX with Mdm2 and the effect of MdmX on Mdm2 stability, we next assessed whether p38 phosphorylates MdmX. Although such phosphorylation was observed in vitro, mutating two conserved putative MAPK sites on MdmX, either singly or together, did not impede p38/MAPK's ability to affect Mdm2 stability, suggesting that other sites may possibly be phosphorylated or that this effect may also depend on other Mdm2-associated proteins.
In assessing MdmX mutants on putative p38 phosphoacceptor sites, we noticed that the S96A mutant exhibits a distinct subcellular localization. Whereas MdmX is normally found within the cytoplasm, the S96A mutant was primarily found within the nucleus (Figure 1 ). This finding pointed to the possible role of MdmX phosphorylation in its subcellular distribution. Further, the cytoplasmic localization of endogenously expressed Mdm2 after expression of MdmX was largely Bacterially expressed His-tagged MdmX wt and S96A mutant forms were purified on nickel beads. Bacterially expressed GSTMdm2 was purified on glutathione beads. Cdc2 was purchased from New England Biolabs Inc. In vitro kinase reactions were performed in the presence of kinase buffer (20 mM HEPES, 2 mM EGTA, 2 mM DTT, 10 mM MgCl 2 , containing 50 mM cold ATP) using Mdm2 or MdmX substrate (0.5 mg) and Cdc2 in the presence of g 32 P-ATP for 30 min at 301C. Beads-bound substrates were subjected to extensive washes before analysis by means of SDS-PAGE-based autoradiography and immunoblots with the indicated antibodies. Quantifications were performed with the aid of a phosphorimager. (b) MdmX and Mdm2 associate with Cdc2. 293T cells were trancfected with the plasmids indicated in the panel 'transfected'. After 24-h, cells were treated with nocodazole for 17 h (to accumulate active Cdc2 levels), followed by cell harvest and immunoprecipitation with Cdc2, MdmX or mouse IgG as control. The blots were probed with MdmX or Cdc2 antibodies to reveal associations between the two proteins. Then 50 mg of whole-cell extract were immunoblotted to reveal expression of MdmX and endogenous Cdc2 Figure 1b and c) . These data pointed to the possible role of MdmX phosphorylation in directing its own localization as well as in localizing Mdm2.
We next set out to identify the kinase that phosphorylates MdmX on S96. Changes in S96A localization were observed under normal growth conditions, excluding the possible role of stress kinases, including p38. Indeed, inhibition of p38 by its specific pharmacological inhibitor (SB203580) did not affect MdmX localization (data not shown). Since the same site can equally serve as a phosphoacceptor site for Cdc2 p34 , we tested the possible role of CDK2/Cdc2 p34 in MdmX phosphorylation. An in vitro kinase reaction using purified active Cdc2 kinase revealed that phosphorylation of MdmX was reduced when S96A was used as a substrate (Figure 2a ). As compared with MdmX, Mdm2 was less efficiently phosphorylated by Cdc2 (Figure 2a shows a short exposure). These data suggest that Cdc2 serves as an MdmX kinase and that S96 is one of the Cdc2 phosphoacceptor sites on MdmX. MdmX (wt and S96A mutant) was found to associate with Cdc2 in vivo, as revealed by immunoprecipitation assays (Figure 2b ). These data suggest that Cdc2 can serve as the MdmX kinase and identify S96 as a Cdc2 phosphoacceptor site.
We next assessed the role of Cdc2 phosphorylation in MdmX and Mdm2 localization. To assess Mdm2 localization, we monitored exogenously expressed Mdm2 and MdmX (wt or mutant) in MdmX/p53 DKO cells. Exogenously expressed wt Mdm2 is found primarily within nuclei, whereas MdmX is localized primarily within the cytoplasm. In contrast, MdmX S96A is localized primarily within the nuclei ( Figure 3A) . Expression of wt MdmX caused efficient nuclear export of Mdm2 to the cytoplasm, whereas the S96A mutant blocked such export and retained Mdm2 within the nucleus, as observed in a series of immunohistochemistry analyses ( Figure 3B -compare columns 2 and 3). Similarly, coexpression of the dominant-negative form of Cdc2 also abolished the MdmX effect and resulted in Figure 3B , columns 4 and 5). Similar effects were observed upon treatment with the pharmacological inhibitor of Cdc2, purvalanol (data not shown). Another MdmX mutant, S314A, had no effects on Mdm2 localization and efficiently caused its export to the cytoplasm ( Figure 3B, column 6 ). Significantly, a phosphomimic mutant of MdmX on its S96 site, S96D, was localized primarily within the cytoplasm and caused efficient export of Mdm2 to the cytoplasm ( Figure 3B, column 7) . These data demonstrate that phosphorylation on S96 of MdmX results in its nuclear accumulation and in inhibition of Mdm2 export to the cytoplasm. The dominant-negative form of Cdc2 (as well as its pharmacological inhibitor) attenuated MdmX accumulation in the cytoplasm and retained Mdm2 within the nucleus. These data suggest that Cdc2 phosphorylation of MdmX is required for its localization within the cytoplasm as well as for export of Mdm2 to the cytoplasm. Nuclear accumulation of Mdm2 is expected to result in alteration of its stability. To test this hypothesis, we monitored steady-state levels of Mdm2 upon expression of wt or mutant forms of MdmX in Mdm2/p53 DKO cells. Coexpression of Mdm2 and MdmX resulted in marked increase in Mdm2 expression levels, in line with earlier studies (Sharp et al., 1999; Tanimura et al., 1999) . In contrast, expression of MdmX S96A was less efficient in increasing Mdm2 expression. Significantly, higher levels of MdmX S96A expression reduced levels of Mdm2 expression (Figure 4a) , suggesting that MdmX S96A may affect Mdm2's stability. Of note, the effect of MdmX on Mdm2 steady-state levels was highly dependent on the relative expression of Mdm2. MdmX S96A ability to reduce Mdm2 expression levels was observed only at lower levels of Mdm2 expression (Figure 4a -compare lane 5 with lane 9). Unlike Mdm2 S96A, neither the S314A nor the S96D forms of MdmX reduced steadystate levels of Mdm2 (Figure 4b) . Support for MdmX S96A ability to reduce stability of Mdm2 comes from an analysis performed in the presence of the proteasome inhibitor lactacystin, which attenuated the MdmX effect (Figure 4c ). To further assess the notion Figure 4 MdmX phosphorylation by Cdc2 is required for stabilization of Mdm2 and p53. (a) Expression of MdmX S96A reduces steady state-levels of Mdm2. Mdm2/p53 double null cells were transfected with Flag-Mdm2 (2 mg; lanes 2-5; 1 mg lanes 6-9), MdmX (1 mg) and MdmX S96A (2,4,6 mg in lanes 3-5 and 2 and 4 mg in lanes 8 and 9, respectively). GFP, 0.25 mg, was cotransfected in all lanes. The total amount of transfected plasmid was equalized with empty vector. Cells were harvested 24 h after transfection and 50 mg of wholecell extract was analysed by means of Western blotting using the indicated antibodies. (b) Mdm2 stability is not reduced by the S96D or S314A forms of MdmX. Mdm2/p53 double null cells were transfected with the indicated plasmids and 24 h later harvested. Whole-cell extract, 50 mg, was used for Western analyses with antibodies to Flag, MdmX, b-actin or GFP. (c) . MdmX S96A reduces Mdm2 stability. Mdm2/p53 DKO cells were transfected with the indicated plasmids and 24 h later cells were subjected to treatment with lactacystin as indicated. Proteins were analysed in immunoblots with the indicated antibodies. (d) Purvalanol attenuates stabilization of Mdm2 by MdmX. Mdm2/p53 DKO cells were transfected with the indicated plasmids and 24 h later, cells were subjected to treatment with Purvalanol (5 and 25 mM for 3 h), as indicated. Whole-cell extract (50 mg) was used for Western blot analysis using the indicated antibodies. An alpha-tubulin Western served as a loading control. (e) MdmX-mediated stabilization of Mdm2 is attenuated upon expression of DN-Cdc2. Mdm2/p53 double null cells were transfected with Flag-Mdm2 (2 mg), MdmX, (3 ml) Cdc2DN (1, 2 and 5 mg corresponding to lanes 4, 5, and 6, respectively) and GFP (0.5 mg). Cells were harvested 24 h later and 50 mg of whole-cell lysate was used for Western analyses using antibodies to proteins indicated on the right panel CDK2/Cdcp34 affect nucelar export of MdmX and Mdm2 B Elias et al that changes observed after expression of the MdmX mutant are due to impaired Cdc2 phosphorylation, we monitored changes in Mdm2 steady-state levels in cells treated with purvalanol. Such treatment also reduced the level of Mdm2 expression, albeit at lower efficiency, probably because of other effects elicited by this drug (Shah et al., 2003; Figure 4d) . Independent support for the role of Cdc2 in Mdm2 stability was obtained upon expression of a DN-Cdc2 construct. Increase in Mdm2 steady-state levels upon coexpression of MdmX was reduced upon expression of DN-Cdc2 (Figure 4e) . Collectively, these data support the role of Cdc2 in the regulation of Mdm2 stability.
Overall, the current set of findings highlights a previously unrecognized layer in the regulation of MdmX and consequently, Mdm2. Since MdmX mutated on the Cdc2 phosphoacceptor site S96 is primarily localized within nuclei, we conclude that Cdc2 phosphorylation is required for MdmX export from nuclei to the cytoplasm. Our data are supported by the finding that an inhibitor of Cdc2 elicits similar effects on MdmX localization. In turn, Mdm2's ability to localize to the cytoplasm is impaired, suggesting that MdmX plays a key role in the nuclear export of Mdm2 from nuclei to the cytoplasm. Consequently, Mdm2's stability appears to be affected, as revealed by reduced steady-state levels of Mdm2 in cells that either express mutant MdmX or the dominant-negative form of Cdc2, as well as in cells treated with the pharmacological inhibitor of Cdc2. These findings suggest that Mdm2 degradation is accelerated upon inhibition of its export to the cytoplasm and that such degradation takes place in the nuclei. Mdm2-dependent degradation of p53 within the nuclei was recently reported (Li et al., 2003) . Along these lines, Li et al have demonstrated that the relative expression level of Mdm2 is important in relation to the type of p53 ubiquitination (mono-vs polyubiquitination). By analogy, our findings also reveal a dosedependent effect of MdmX on Mdm2, as its ability to decrease Mdm2 stability is seen only when levels of Mdm2 are reduced, suggesting that such regulation depends on the relative availability of Mdm2. Since CDK1/Cdc2 was also shown to phosphorylate Mdm2 in a manner that affects its interaction with other proteins (Zhang and Prives, 2001) , it is possible that such phosphorylation may also affect MdmX ability to affect Mdm2. Our studies cannot exclude the possibility that CDK2 is also capable of eliciting such changes, a point that requires further investigation. It is equally plausible that Cdc2/CDK2 phosphorylation of MdmX takes place primarily at a specific phase of the cell cycle, which would implicate cell cycle regulation of Mdm2 export to the cytoplasm, in line with changes observed in Mdm2 levels in a cell-cycle-dependent manner.
